Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Agenus - You Need To See This

Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development

Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer.

Benzinga · Nov 27, 2024

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga · Aug 1, 2022

Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer

Agenus Inc (NASDAQ:AGEN) has announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer. The data demonstrate that the combination offers strong durability and superior efficacy to what has been reported in separate trials for the standard of care and other investigational therapies. The…

Benzinga · Jun 29, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Agenus's Return On Capital Employed Insights

According to Benzinga Pro data, during Q1, Agenus (NASDAQ:AGEN) posted sales of $25.94 million. Earnings were up 25.15%, but Agenus still reported an overall loss of $50.60 million.

Benzinga · Jun 8, 2022

Recap: Agenus Q1 Earnings

Agenus (NASDAQ:AGEN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga · May 10, 2022

Looking Into Agenus's Return On Capital Employed

Benzinga Pro data, Agenus (NASDAQ:AGEN) reported Q4 sales of $20.26 million. Earnings fell to a loss of $67.61 million, resulting in a 138.14% decrease from last quarter. Agenus earned $177.28 million, and sales totaled $252.95 million in Q3.

Benzinga · Mar 3, 2022

Recap: Agenus Q4 Earnings

Agenus (NASDAQ:AGEN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 1, 2022

Read news from The Economist, FT, and more,
with one subscription

Coverage From

Benzinga

Organisations

Food and Drug Administration

353 stories

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,089 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.